Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma

2000234 citationsJournal Article

Authors

Good health and well-being

Published in: European Journal of Nuclear Medicine and Molecular Imaging

Volume 27, Issue 7, pp. 766-777

Field-Weighted Citation Impact: 13.67